These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 16539392

  • 1. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
    Seto M, Aikawa K, Miyamoto N, Aramaki Y, Kanzaki N, Takashima K, Kuze Y, Iizawa Y, Baba M, Shiraishi M.
    J Med Chem; 2006 Mar 23; 49(6):2037-48. PubMed ID: 16539392
    [Abstract] [Full Text] [Related]

  • 2. Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety.
    Seto M, Miyamoto N, Aikawa K, Aramaki Y, Kanzaki N, Iizawa Y, Baba M, Shiraishi M.
    Bioorg Med Chem; 2005 Jan 17; 13(2):363-86. PubMed ID: 15598559
    [Abstract] [Full Text] [Related]

  • 3. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
    Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, Shiraishi M, Iizawa Y.
    Antimicrob Agents Chemother; 2005 Nov 17; 49(11):4584-91. PubMed ID: 16251299
    [Abstract] [Full Text] [Related]

  • 4. Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
    Imamura S, Ichikawa T, Nishikawa Y, Kanzaki N, Takashima K, Niwa S, Iizawa Y, Baba M, Sugihara Y.
    J Med Chem; 2006 May 04; 49(9):2784-93. PubMed ID: 16640339
    [Abstract] [Full Text] [Related]

  • 5. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
    Takashima K, Miyake H, Kanzaki N, Tagawa Y, Wang X, Sugihara Y, Iizawa Y, Baba M.
    Antimicrob Agents Chemother; 2005 Aug 04; 49(8):3474-82. PubMed ID: 16048963
    [Abstract] [Full Text] [Related]

  • 6. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist.
    Tagat JR, McCombie SW, Nazareno D, Labroli MA, Xiao Y, Steensma RW, Strizki JM, Baroudy BM, Cox K, Lachowicz J, Varty G, Watkins R.
    J Med Chem; 2004 May 06; 47(10):2405-8. PubMed ID: 15115380
    [Abstract] [Full Text] [Related]

  • 7. CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives.
    Imamura S, Nishikawa Y, Ichikawa T, Hattori T, Matsushita Y, Hashiguchi S, Kanzaki N, Iizawa Y, Baba M, Sugihara Y.
    Bioorg Med Chem; 2005 Jan 17; 13(2):397-416. PubMed ID: 15598561
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent.
    Ma D, Yu S, Li B, Chen L, Chen R, Yu K, Zhang L, Chen Z, Zhong D, Gong Z, Wang R, Jiang H, Pei G.
    ChemMedChem; 2007 Feb 17; 2(2):187-93. PubMed ID: 17163560
    [Abstract] [Full Text] [Related]

  • 9. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
    Takashima K, Miyake H, Furuta RA, Fujisawa JI, Iizawa Y, Kanzaki N, Shiraishi M, Okonogi K, Baba M.
    Antimicrob Agents Chemother; 2001 Dec 17; 45(12):3538-43. PubMed ID: 11709336
    [Abstract] [Full Text] [Related]

  • 10. CCR5 antagonists as anti-HIV-1 agents. Part 2: Synthesis and biological evaluation of N-[3-(4-benzylpiperidin-1-yl)propyl]-N,N'-diphenylureas.
    Imamura S, Kurasawa O, Nara Y, Ichikawa T, Nishikawa Y, Iida T, Hashiguchi S, Kanzaki N, Iizawa Y, Baba M, Sugihara Y.
    Bioorg Med Chem; 2004 May 01; 12(9):2295-306. PubMed ID: 15080927
    [Abstract] [Full Text] [Related]

  • 11. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, Koyanagi Y, Mitsuya H.
    J Virol; 2004 Aug 01; 78(16):8654-62. PubMed ID: 15280474
    [Abstract] [Full Text] [Related]

  • 12. Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication.
    Skerlj R, Bridger G, Zhou Y, Bourque E, McEachern E, Langille J, Harwig C, Veale D, Yang W, Li T, Zhu Y, Bey M, Baird I, Sartori M, Metz M, Mosi R, Nelson K, Bodart V, Wong R, Fricker S, Mac Farland R, Huskens D, Schols D.
    Bioorg Med Chem Lett; 2011 Dec 01; 21(23):6950-4. PubMed ID: 22033460
    [Abstract] [Full Text] [Related]

  • 13. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
    Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M.
    Antimicrob Agents Chemother; 2005 Nov 01; 49(11):4721-32. PubMed ID: 16251317
    [Abstract] [Full Text] [Related]

  • 14. Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
    Wang T, Zhang Z, Wallace OB, Deshpande M, Fang H, Yang Z, Zadjura LM, Tweedie DL, Huang S, Zhao F, Ranadive S, Robinson BS, Gong YF, Ricarrdi K, Spicer TP, Deminie C, Rose R, Wang HG, Blair WS, Shi PY, Lin PF, Colonno RJ, Meanwell NA.
    J Med Chem; 2003 Sep 25; 46(20):4236-9. PubMed ID: 13678401
    [Abstract] [Full Text] [Related]

  • 15. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
    Shin N, Solomon K, Zhou N, Wang KH, Garlapati V, Thomas B, Li Y, Covington M, Baribaud F, Erickson-Viitanen S, Czerniak P, Contel N, Liu P, Burn T, Hollis G, Yeleswaram S, Vaddi K, Xue CB, Metcalf B, Friedman S, Scherle P, Newton R.
    J Pharmacol Exp Ther; 2011 Jul 25; 338(1):228-39. PubMed ID: 21459966
    [Abstract] [Full Text] [Related]

  • 16. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.
    Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, Ito M, Koyanagi Y, Mitsuya H.
    J Virol; 2005 Feb 25; 79(4):2087-96. PubMed ID: 15681411
    [Abstract] [Full Text] [Related]

  • 17. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds.
    Shen DM, Shu M, Willoughby CA, Shah S, Lynch CL, Hale JJ, Mills SG, Chapman KT, Malkowitz L, Springer MS, Gould SL, DeMartino JA, Siciliano SJ, Lyons K, Pivnichny JV, Kwei GY, Carella A, Carver G, Holmes K, Schleif WA, Danzeisen R, Hazuda D, Kessler J, Lineberger J, Miller MD, Emini EA.
    Bioorg Med Chem Lett; 2004 Feb 23; 14(4):941-5. PubMed ID: 15012998
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
    Habashita H, Kokubo M, Hamano S, Hamanaka N, Toda M, Shibayama S, Tada H, Sagawa K, Fukushima D, Maeda K, Mitsuya H.
    J Med Chem; 2006 Jul 13; 49(14):4140-52. PubMed ID: 16821774
    [Abstract] [Full Text] [Related]

  • 19. Orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activity of 1-benzothiepine 1,1-dioxide and 1-benzazepine derivatives containing a tertiary amine moiety.
    Seto M, Aramaki Y, Okawa T, Miyamoto N, Aikawa K, Kanzaki N, Niwa S, Iizawa Y, Baba M, Shiraishi M.
    Chem Pharm Bull (Tokyo); 2004 May 13; 52(5):577-90. PubMed ID: 15133211
    [Abstract] [Full Text] [Related]

  • 20. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
    Skerlj RT, Bridger GJ, Kaller A, McEachern EJ, Crawford JB, Zhou Y, Atsma B, Langille J, Nan S, Veale D, Wilson T, Harwig C, Hatse S, Princen K, De Clercq E, Schols D.
    J Med Chem; 2010 Apr 22; 53(8):3376-88. PubMed ID: 20297846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.